☆ 4.6 Meeting Abstract

NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PEDIATRIC PATIENTS WITH HIGH-GRADE CNS MALIGNANCIES: EFFICACY, SAFETY, BIOMARKER, AND PHARMACOKINETIC RESULTS FROM CHECKMATE 908

NEURO-ONCOLOGY (2022)

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN PEDIATRIC PATIENTS WITH HIGH-GRADE CNS MALIGNANCIES: EFFICACY, SAFETY, BIOMARKER, AND PHARMACOKINETIC RESULTS FROM CHECKMATE 908

Rate this paper

Add your recorded webinar

Create your own webinar

Export Citation

Share Paper